• Hematologic malignancies: CONUT simplifies prediction of transplant outcomes

    Poor CONUT is an independent predictor of early nonrelapse mortality.

  • Chronic-phase CML: frontline nilotinib delivers high-level response, adherence

    1 in 3 achieved undetectable molecular disease at 24 months.

  • NHL: study identifies 2 risk factors for rituximab infusion reactions

    Findings may help inform beneficial infusion modifications.

  • CML-CP: imatinib delivers excellent response with low toxicity in very old patients

    7 in 10 patients achieved complete cytogenetic response.

  • AML: add-on nivolumab safe, effective with standard induction therapy

    Median EFS not reached at time of analysis.

  • Frontline AML: real-world data confirm decitabine safety, efficacy

    Adverse cytogenetics, higher WBC predicted inferior survival.

  • MDS: certain demographic factors prognostic of favorable survival

    Factors including married status prognostic of favorable survival.

  • CLL: ibrutinib delivers improved survival vs conventional 2L therapies

    Venetoclax may be a better option in patients with 13q14.3 deletion.

  • Anti-CD19 + BCMA-targeted CAR T infusion delivers high response in myeloma

    81% achieved minimal residual disease negativity.

  • Frontline ibrutinib-rituximab tops chemoimmunotherapy for CLL

    65% reduction in risk for progression or death.

  • Remission with ibrutinib + venetoclax in relapsed chronic lymphocytic leukaemia

    Findings from the CLARITY trial published in the Journal of Clinical Oncology

  • R/R DLBCL: ibrutinib, lenalidomide, rituximab regimen promising in non-GCB disease

    Median duration of response not reached in patients with complete response.

  • Advanced Hodgkin lymphoma: 5-year data show limited PET2 predictive power

    1 in 4 PET2-negative patients experienced progression at 5 years.

  • Secondary CNS lymphoma: tisagenlecleucel active with low neurotoxicity risk

    Largest cohort of its kind in this setting.

  • NICE recommends letermovir for preventing CMV disease after stem cell transplant
    NICE recommends letermovir for preventing CMV disease after stem cell transplant

    The drug could reduce the need for pre-emptive therapy which is associated with serious side effects.

  • Follicular lymphoma: rituximab maintenance yields sustained PFS benefit at 9 years

    Data from the phase 3 PRIMA trial.

  • FDA prompts recall of Allergan's textured breast implants tied to anaplastic large-cell lymphoma

    Allergan issues recall of BIOCELL textured implants and tissue expanders.

  • Load more